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Abstract: Fit testing procedure is required for filtering facepiece respirators (FFRs) to ascertain an
acceptable fit between the skin and facepiece sealing surface. The present study seeks to compare
the efficacy of Aloe vera (A. vera) and commercial BitrexTM as challenge agents of qualitative fit
testing of particulate respirators. An herbal solution consisting of A. vera at seven different concentrations was developed. Threshold Screening Tests (TSTs) of A. vera solutions were compared to
BitrexTM. To do so, solutions were administered randomly on a total of 62 participants. A placebo
was also tested to ensure the taste response being valid. Statistical analysis was performed using R
3.2.5.0 software. There were no statistically significant differences between the A. vera (41.7, 58.3,
75, and 91.7 mg/ml) and BitrexTM threshold tests. Therefore, the minimum concentration of A. vera
to develop the threshold solution was considered to be 41.7 mg/ml. When commercial products are
expensive and unavailable, a cost-effective technique would be to replace A. vera solution with a
commercial product as a challenge agent of qualitative fit testing of respirators.
Key words: Qualitative Fit test, Challenge agents, Commercial and herbal solutions

Introduction
Efficient respiratory protection is dependent mainly on
the filters or cartridges efficiency as well as appropriateness for users’ face and work environment1–3). According
to the Occupational Safety and Health Administration
(OSHA), it is mandatory to make sure there is an appropriate fit between a respirator’s facepiece and face seal. To
meet the legal requirements, it is necessary to do fit testing
*To whom correspondence should be addressed.
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for all subjects included in the Respiratory Protection Program (RPP) before the respirator selection4). The ability of
the respirator to interface with the users’ face to protect the
respiratory system against hazardous contaminants, named
“Respirator fit”5).
There are mainly two assessment methods of respirator fit testing per OSHA standard (29 CFR 1910.134), to
provide the expected level of protection for the wearers6):
Qualitative fit test (QLFT) and Quantitative fit test (QNFT).
QNFT uses an instrument to measure the fit factor by dividing the ambient particle concentration by the concentration of particles inside the facepiece of the respirator while
the user performs a series of simulated work exercises4).

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives (by-nc-nd) License.
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QNFT has some advantages such as application to various classes of Respiratory Protective Equipment (RPE)7),
documentation of numerical results, and no chance of
deception8). However, due to high cost, time-consuming,
skilled operator, unavailability5), annual recalibration, and
reliance on a sampling adaptor or probed respirator, QLFT
is widely being used as the preferred method4, 9, 10).
QLFT is a dichotomous test (pass/fail) that depends
on the wearer’s olfactory or taste response to a challenge
agent during the same series of exercises as the QNFT.
Currently, there are three common challenge agents including isoamyl acetate; saccharin; and BitrexTM. Isoamyl
acetate (IAA), a sweet (banana) smelling vapor is used in
qualitative fit testing of respirators equipped with organic
vapor cartridges; whereas, saccharin (sweet taste) and BitrexTM (bitter taste) are the challenge agents for fit testing
of respirators equipped with particulate filters4). Moreover,
BitrexTM, the trade name of the bitterest substance, denatonium benzoate (Smith Ltd., Montvale, NJ McFarland),
generally used as an aversive agent in toxic household
liquids to decrease the risk of accidental poisoning4).
The most substantial concern about the QLFT is its subjective nature. It is impossible to do fit testing for all subjects
in events like pandemics11). It should be mentioned that the
QLFT is simpler to use11, 12), and cheaper to set up and maintain12) than QNFT. But some of the challenge agents like BitrexTM lead to allergic (asthmatic) reactions13, 14), dermal and
respiratory symptoms, anaphylactic reactions (angioedema
and bronchospasm), and anxiety response or even an inability
to detect the taste/smell of the agents13).
Remarkably, some qualifications should be considered
for selecting a qualitative challenge agent as follows: costbenefit, availability, safety, suitability for human exposure,
and ability to use with any type of approved particular
filter12). Commercial challenge agents would not be costbeneficial or available, furthermore, they might be led to
symptoms and complications in some subjects as mentioned above. Consequently, the efficacy of A. vera was
compared to BitrexTM.
A. vera is a shining or bitter substance, bitter because of
liquids such as Aloin, Aloe emodin, and related compounds
in the leaves15–17). It is approved as Generally Recognized
as Safe (GRAS) in the US by the Food and Drug Agency
(FDA)16, 18) and World Health Organization (WHO)18, 19).
It exerts beneficial effects on human health, including:
anti-inflammatory 17, 18, 20–25), antimicrobial 18, 22–24, 26),
antifungal17, 18), antioxidant and antitumor 23, 27), anticancer17, 23, 26, 28), and immunomodulatory properties17, 23, 24). It
seems that A. vera could be the right substitute for BitrexTM

as a challenge agent. Also, as stated in ISO 16975-3 9),
equivalent substances could be used as challenge agents if
they behave similar and show identical results. Accordingly,
the aim of this study was to compare the efficacy of A. vera
against BitrexTM as a qualitative fit test agent.

Subjects and Methods
Study design
We conducted a single-blind, placebo-controlled, and
interventional study at Shiraz University of Medical Sciences, Iran.
Participants
Sixty-two students (37 females and 25 males), mean age
23.45 ± 4.66 yr, using a proportional stratified sampling
method based on their educational level, were recruited
for the study. The participants were tested in the Industrial
Safety laboratory of the School of Health.
First of all, the procedures of this study were approved
by the Research Ethics Committee of Shiraz University of
Medical Sciences (approval code IR.SUMS.REC.1396.191).
Second, all participants were provided explanation about
study procedures. Then, each was given written informed
consent documentation. The criteria included an absence of
the following: (1) allergy to any substance; (2) cold symptoms; (3) nasal congestion; (4) cardiovascular or respiratory
diseases (asthma, shortness of breath, dyspnea);29) rhinoplasty surgery, or (6) other factors interfering with the sense
of taste. If any participant developed a cold, the test session
was postponed until his/her recovery.
Study procedure
All participants refrained from chewing gum, eating,
and drinking (except for plain water) for 15 min prior to
the test to ensure they could taste the threshold check solution (a diluted version of the fit test solution). Meanwhile,
the placebo solution (distilled water) was tested among
the solutions randomly to be sure the participants could
distinguish it. To obtain reliable results, the test assessor
reminded participants to drink only plain water. A 5-min
break also allowed participants to clear their palates between test solutions. These adopted complementary tests
were illustrated further:
1) To make certain the threshold check solutions hadn’t
been contaminated, the microbial communications of the
solutions were assessed. To do so, we utilized the Blood
Agar for bacteria 30) and Sabouraud Dextrose Agar 31)
(Merck Co., Germany) for fungus.
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Table 1.

Results of the Threshold Screening Tests (TSTs)

Solutions
Placebo
BitrexTM

pH

Pass
N (%)

--

-

44 (71)

0. 135
10.7

A. vera

Threshold test

Concentration
(mg/ml)

Number of sprays

Detection time (S)

Fail
N (%)

Mean ± SD

Mean ± SD

18 (29)*

15.68 ± 8.04

22.08 ± 11.49

6.91

60 (96.8)

2 (3.2)

5.32 ± 4.18

7.96 ± 4.96

7.50

52 (83.9)

10 (16.1)

7.54 ± 6.32

11.02 ± 7.58

18.8

7.11

43 (69.4)

19 (30.6)

7.65 ± 5.83

10.84 ± 6.8

26.2

7.02

43 (69.4)

19 (30.6)

8.81 ± 7.22

13.58 ± 11.33

41.7

6.70

53 (85.5)

9 (14.5)

7.04 ± 6.016

9.75 ± 6.97

58.3

6.43

53 (85.5)

9 (14.5)

6.87 ± 4.87

9.43 ± 6.01

75.0

6.25

57 (91.9)

5 (8.07)

6.23 ± 5.68

9.12 ± 7.43

91.7

6.14

53 (85.5)

9 (14.51)

4.81 ± 3.07

7.27 ± 3.54

*18 (29%) of the participants reported the placebo as a sweet, salty, or bitter taste.

2) The taste of the solutions was evaluated continuously.
3) The optical molecular spectra of the solutions was
observed regularly using Agilent Cary 60 spectrophotometer
(Agilent Technologies, Santa Clara, CA, USA) at 25°C in the
wavelength range of 200–800 nm to follow up the stability
of the solutions regarding color, clarity and not construction
of unstable colloids during the ten months which were presented in the Supplementary Figs. 1–8 (See online version).
4) The pH of the solutions was measured using a Metrohm pH meter model 827 (Metrohm, Herisau, Switzerland), according to manufacturer’s instructions (Table 1).
Threshold check solution preparation
Nine different threshold check solutions, including A.
vera (7 concentrations), a BitrexTM, and a placebo, were
made. We found that limited amounts of A. vera could not
significantly affect the taste of the solutions; therefore,
they were considered for the range of applied concentrations of the A. vera threshold check solutions. The threshold check solutions were poured into identical bottles and
labeled with unique codes by the administrator. Those
solutions were randomly allocated to the participants
based on the Latin Square Design (LSD)12). Accordingly,
all possible permutation of solutions was 9 factorial (9!).
Also, all participants were blinded to the ingredient and
concentration of each solution.
BitrexTM threshold check solution
Moldex® Bitrex® Fit Test Kit Part number 0102 (Moldex
Co., Culver, CA, USA) contained 0.0135% denatonium
benzoate, 94.9865% water, and 5% sodium chloride32).
Aloe vera threshold check solution
We chose the A. vera as equivalent to BitrexTM. A. vera

solutions were prepared by adding 1.28, 2.26, 3.15, 5, 7,
9, and 11 gr of A. vera powder to 120 ml of distilled water.
The above mixtures were boiled at 100°C for 10 min.
After the solutions had been cooled, they were passed
through a stainless sieve (US Standard Sieve Mesh No. 200
(0.075 mm), Pars Sieve, Iran; ASTM E:11). Indeed, the final
concentrations of the threshold check solutions 10.7, 18.8,
26.2, 41.7, 58.3, 75, and 91.7 mg/ml, respectively.
Threshold Screening Tests
Threshold Screening Tests (TSTs) were performed
per OSHA respiratory protection standard, regulation
29 CFR 1910.1344). The TSTs were aimed to ensure the
participants’ taste response being valid. Some accessories
are required to do the TSTs, for instance, hood, nebulizer,
and paper towel. The poly-coated test hood is approximately 12 inches (30.5 cm) in diameter by 14 inches
(35.6 cm) and was placed over a participant’s head and
positioned forward about 6 inches (15.25 cm) between
the participant’s face and hood window. The 0.75 inch
(1.9 cm) hole in front of the participant’s nose and mouth
area accommodated the nebulizer nozzle and dispersed the
aerosol with a 2.5 µm mass median aerodynamic diameter
(MMAD) around the participant’s mouth9) (Fig. 1). Moreover, the nebulizers were periodically checked for aerosol
generation while squeezing the bulbs. To do so, they were
held against a dark background to ensure the visible aerosol appears. The nebulizers were disassembled based on
the manufacturer’s manual and rinsed at regular intervals
to prevent clogging. The hood was wiped frequently with
a paper towel to clean any deposited solution.
Prior to starting the intervention, firstly, the participants
were trained to position the hood over the head without
donning a respirator, breathing only through their mouths
Industrial Health 2020, 58, 46–53
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Fig. 1.

Moldex fit test hood used in the current study.

The Area under the ROC Curve (AUC) was calculated
to determine the overall performance of all threshold
check solutions against the placebo35). Additionally, A.
vera threshold solutions (bitter taste) were compared to
BitrexTM (as a reference solution). A p-value of 0.05 was
considered significant. All data analyses were performed
using R 3.2.5.0 software.

Results
slightly open with tongue extended and to report as soon as
they could detect the taste (not smell) of the challenge agent,
however, we didn’t notify the participants about the taste
of the solutions (sweet, bitter, etc.). Secondly, the challenge
agent was injected in the hood via inserting ten squeezes of
the nebulizer bulb into the hole in front of the hood. This
requires the bulb to fully collapse and expand during each
squeeze cycle. Thirdly, the participants were asked if they
could detect the taste of the solution. We applied up to a
total of 30 sprays if required. Also, the taste threshold was
recorded as ten, twenty, or thirty regardless of the numbers
of actual performed squeezes (10, 20 or 30 sprays). In other
words, if the participants could taste between 1–10, 11–20,
or 21–30 sprays, their threshold levels were classified into
one of the three classes of High (1), Medium (2), or Low
(3), respectively. If the participants couldn’t detect the taste
of the solution after 30 sprays, they were not sensitive to it
and their threshold test was assigned as a failure; otherwise,
a pass. The video of Moldex threshold screening procedure
was played for the participants33).
Lastly, we recorded the study data such as threshold solution code, the concentration of test solutions (mg/ml), number
of sprays, time required to elicit a taste response correctly (s),
threshold level (1, 2 or 3), and test result (pass/fail).
Statistical analysis
The input variables were as follows: type and concentration of the solutions, age, and gender. The outcome
variables included the results of TSTs (pass/fail). We took
repeated measures on the participants; thus, the observations were correlated and the Mixed Effect Logistic
Regression (MELR) model including random effects was
proposed34). Noticeably, the model was adjusted for age
and gender. We calculated the Kappa statistic (k), Brier
score as the mean square error of taste detection34), and accuracy35) to compare the results of the TSTs. Meanwhile,
a Receiver Operating Characteristic (ROC) curve analysis
was obtained to evaluate the detectability of all threshold solutions against placebo (as a reference solution).

Table 1 shows the TSTs descriptive statistics results.
As shown, the majority of the participants could taste
BitrexTM and A. vera (75 mg/ml) solutions (96.8% and
91.9%, respectively). As expected, all solutions (except for
placebo) were tasted within close margin, in terms of the
number of sprays and detection time(s).
The results of all threshold solutions tests against
placebo are shown in Table 2. There were significant differences between the BitrexTM and A. vera solutions (41.7,
58.3, 75, and 91.7 mg/ml) and placebo. The odds ratio
(OR) for taste detection of BitrexTM and A. vera (75 mg/
ml) was calculated as 14.78 and 5.39, respectively. In addition, the accuracy score for the corresponding solutions
was the highest as 84% (104/124) and 81% (101/124),
respectively. The A. vera (75 mg/ml) held the lowest Brier
score among all solutions.
The ROC curves for BitrexTM and A. vera threshold
tests against placebo are given in Fig. 2. Accordingly, the
ROC curve for A. vera threshold test was similar to that
of BitrexTM (89.5% vs. 90.3%, respectively). The numbers
represent the participants could detect the bitter taste of
BitrexTM and A. vera (75 mg/ml) during TSTs. This suggests that the performance of A. vera threshold solution
(75 mg/ml) was similar to that of BitrexTM.
The results of A. vera threshold tests against BitrexTM
are summarized in Table 3. As seen, no significant differences were found between the A. vera (concentration
range of 41.7 to 91.7 mg/ml) and Bitrex TM threshold
tests. Among all solutions, the OR for taste detection of
A. vera (75 mg/ml) in comparison to BitrexTM was the
highest (OR=0.37). The significant agreement between
the BitrexTM and A. vera (75 mg/ml) threshold tests was
calculated as the highest value (k=0.88).
Figure 3 reveals the overall performance of BitrexTM
and A. vera threshold tests against a placebo through comparing the correspondence AUC curves. Obviously, the
AUC curves for those solutions overlapped. No significant
differences were observed between the BitrexTM and A.
vera threshold tests (p=0.66). Since the ROC curve for the
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Table 2.

Comparison of threshold tests against placebo by MELR*

Solutions
Commercial

Concentration
(mg/ml)

Coefficient
(β)

OR

0.135

2.69**

95% CI for OR

Accuracy

Brier Score

Lower

Upper

14.78

3.15

0.18

0.84

0.32

AUC

95% CI for AUC
Lower

Upper

0.9

0.85

0.95

BitrexTM
A. vera

10.7

0.84

2.32

0.92

0.05

0.78

0.14

0.85

0.78

0.91

18.8

−0.09

0.92

0.40

0.14

0.71

0.39

0.76

0.68

0.83

26.2

−0.09

0.92

0.40

0.39

0.72

0.31

0.78

0.71

0.85

41.7

0.98***

2.65

1.03

0.31

0.78

0.14

0.85

0.79

0.92

58.3

0.98***

2.65

1.03

0.14

0.78

0.13

0.85

0.79

0.92

75.0

1.68***

5.39

1.78

0.13

0.81

0.05

0.89

0.84

0.95

91.7

0.98***

2.65

1.03

0.048

0.78

0.11

0.86

0.8

0.92

*Adjusted for age/gender, **p-value<0.0001, ***p-value<0.05.
MELR: Mixed Effect Logistic Regression; CI: confidence interval; OR: odds ratio; AUC: Area under the ROC Curve.

Fig. 2. Receiver operating characteristic (ROC) curves for threshold tests against placebo: BitrexTM(a), A. vera;
41.7 and 58.3 mg/ml (b), 75 mg/ml (c), 91.7 mg/ml (d).

Industrial Health 2020, 58, 46–53
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Table 3.

The results of A. vera threshold tests vs. commercial BitrexTM by MELR*

Solutions
A. vera

Concentration
(mg/ml)

Coefficient
(β)

OR

10.7

−1.85**

18.8

−2.77***

26.2

95% CI for OR
Lower

Upper

0.16

0.03

0.78

0.06

0.01

0.29

−2.77***

0.06

0.01

41.7

−1.71

0.18

58.3

−1.71

75.0
91.7

Kappa (k)

95% CI for Kappa
Lower

Upper

0.82

0.71

0.92

0.69

0.57

0.82

0.29

0.69

0.57

0.82

0.04

0.09

0.82

0.71

0.92

0.18

0.04

0.09

0.85

0.75

0.94

−1.00

0.37

0.07

2.02

0.88

0.79

0.97

−1.71

0.18

0.04

0.09

0.85

0.75

0.94

* Adjusted for age/gender, **p-value<0.05, ***p-value<0.0001.
MELR: Mixed Effect Logistic Regression; CI: confidence interval; OR: odds ratio.

Fig. 3. Comparison of area under the ROC curves (AUC) for threshold solutions: BitrexTM and A. vera; 75 mg/ml
(a), 41.7, 58.3, and 75 mg/ml (b).

A. vera (75 mg/ml) threshold solution moved to left and
upside (BitrexTM), it is apparent that its efficacy is similar
to that of BitrexTM and could be employed as a qualitative fit test agent. Interestingly, the Cost-Benefit Analysis
(CBA) of the current study indicates that the cost and
time required to access A. vera solution were remarkably
less than BitrexTM one (Where cost is $84/100 gr versus
$2/100 gr, and time between purchase and delivery is 1
business day versus 14 business days).

Discussion
The aim of this study is to investigate the efficacy of
A. vera compared to BitrexTM as a qualitative challenge

agent. The principal points found from this research will
be discussed below in more detail.
First, the proposed MELR model demonstrated that
there were no statistically significant differences between
the BitrexTM and A. vera (41.7, 58.3, 75, and 91.7 mg/ml)
threshold test results. This means that participants could
detect the bitter taste using either BitrexTM or A. vera solution. The minimum concentration of A. vera to develop the
threshold solution was considered be 41.7 mg/ml. Accordingly, A. vera solution could be made on-site with similar
efficacy to that of BitrexTM.
Second, the degree of agreement between the results
of BitrexTM and A. vera (75 mg/ml) threshold tests was
considered very good (k=0.88) which highlights the high
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efficacy of A. vera in order to use as a qualitative fit test
agent. This finding is consistent with the study of Brett G.
Mitchell et al.11), which states that on-site made solutions
could be replaced by commercial products for qualitative
fit testing of respirators. The ability to produce A. vera solution on-site is a critical factor to making a key difference
in the event of an influenza pandemic or similar respiratory diseases. If the testing solution was either not readily
available or too costly, the facility could incur preventable
loss of both profit and life.
Another important finding has to do with the fact that
the majority of the participants tasted both the BitrexTM
and A. vera (75 mg/ml) solutions. The OR for taste detection of these mentioned solutions was 14.78 and 5.39
times the OR for the placebo, respectively, meaning that
the OR for taste detection of the Bitrex TM was almost
2.70 times the OR for taste detection of A. vera (75 mg/
ml) solution. This means that participants were 2.70 times
more likely to detect the bitter taste of BitrexTM than that
of A. vera (75 mg/ml) solution. The AUC for those solutions overlapped, which confirms that A. vera (75 mg/ml)
solution has similar efficacy to that of BitrexTM.
Noticeably, BitrexTM was detected more often than A.
vera (75 mg/ml) (96.8% vs. 91.9%). This is consistent with
some published studies (Mullins, 1995; Roy T. McKay,
2000) that discussed easier detectability of BitrexTM compared with saccharin12, 36). The mean of the sprays’ number
to detect the bitter taste of BitrexTM and A. vera (75 mg/
ml) were almost the same (5.32, 6.23, respectively). We
can also merge those two thoughts as “The CBA obtained
from the laboratory test confirm that A. vera (75 mg/ml)
could be utilized as a challenge agent of qualitative fit test,
which is beneficial”.
The overall cost of A. vera was 42 times (97.6%) lower
than that of BitrexTM. Additionally, the required time for
preparation of A. vera fit test solution was lower than that of
BitrexTM. In fact, on an average, 14 business days required
for the commercial solution to be delivered. Whereas, the A.
vera could be available about one business day.
Finally, a number of important limitations need to be considered. First, the TSTs of the current study were based on
the subjective reaction to the challenge agents like the other
qualitative fit test solutions. Second, any variation from the
fit test protocol would invalidate the test results, including
the hood size, changes in the concentration of the solutions,
squeezing the nebulizer bulb, and the number of squeezes.

A FAKHERPOUR et al.

Conclusion
This study suggests that replacing of A. vera solution
with a commercial product as a challenge agent in fit testing procedure would be a cost-effective technique; due to
factors as performance, cost, and availability. It should be
emphasized that the studied solutions are safe for microbial communications and some physicochemical properties
of the solutions (taste, color or clearance) were monitored
over the course of the study and we can safely assure that
these properties are constant. To do so, it is feasible to utilize the herbal solutions (i.e., A. vera) as challenge agents
for qualitative fit testing of particulate respirators.
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